UBS initiates Elekta at “sell,” cites slowing radiotherapy market and 30% downside

UBS has initiated coverage of Elekta AB (ST:EKTAb) with a 'sell' rating and a SEK34 price target, implying a 30% downside from its September 2 closing price. This bearish outlook stems from a weakening global radiotherapy market, Elekta's limited ability to leverage its new Evo platform for widespread adoption, and persistent market share losses. Furthermore, UBS projects market growth at 3-4%, half of Elekta's forecast, and notes the company's premium valuation despite weaker free cash flow conversion and 'deep structural risks' to its operating model, anticipating Elekta's upcoming Q2 operating profit to miss consensus by 6%.

Analysis

UBS has initiated coverage on Elekta AB (ST:EKTAb) with a decidedly bearish outlook, issuing a 'sell' rating and a SEK34 price target, which implies approximately 30% downside from its recent closing price. The core of the thesis rests on a multi-faceted critique of both market conditions and company-specific fundamentals. UBS projects the global radiotherapy market will grow at only 3-4% in the medium term, directly challenging Elekta's far more optimistic 6-8% forecast and suggesting sell-side consensus is also too high. This market headwind is attributed to slowing volumes in developed markets and the threat of disruption from Chinese competitors in emerging markets. Compounding this, UBS is skeptical of the company's new Evo platform, arguing its key feature of adaptive radiotherapy will fail to gain widespread adoption, thus being unable to reverse Elekta's decade-long market share loss to rival Varian. On valuation, UBS contends that despite appearing inexpensive, the stock is actually expensive, trading at a premium to peers while exhibiting weaker free cash flow conversion and facing 'deep structural risks.' A near-term catalyst is the upcoming Q2 earnings on November 26, for which UBS anticipates operating profit will miss consensus estimates by 6%.

Key Decisions for Investors

• Given the 'sell' rating, a 30% projected downside, and deep structural risks highlighted by UBS, investors holding Elekta should critically re-evaluate their positions.
• The significant discrepancy between Elekta's 6-8% growth guidance and UBS's 3-4% market forecast, coupled with a predicted earnings miss, presents a clear short thesis, particularly leading into the November 26 earnings report.
• Monitor the adoption and market reception of the new Evo platform, as its failure to gain traction would validate UBS's core concern and likely pressure the stock further.
• Investors should treat the stock's valuation with caution, as UBS's analysis suggests it does not adequately price in weaker free cash flow conversion and intensifying competitive and market-level headwinds.